Physician profile
Lawrence Zumo
NPI 1093882680
$2,963.53
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $449 · 2021: $813 · 2022: $663 · 2023: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $794.86 | 2019-2023 | |
| Biogen, INC. | $605.66 | 2019-2023 | Vumerity, Tysabri |
| Abbvie INC. | $227.10 | 2021-2023 | Ubrelvy |
| Lilly USA, LLC | $187.59 | 2019-2023 | Amyvid |
| Genzyme Corporation | $132.45 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $115.33 | 2023 | Aptiom |
| Ucb, INC. | $108.04 | 2021-2022 | |
| Argenx US, INC. | $90.21 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Biohaven Pharmaceuticals, INC. | $87.00 | 2020-2021 | |
| Allergan, INC. | $84.92 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $84.69 | 2021 | |
| Novo Nordisk INC | $64.63 | 2020 | |
| Vanda Pharmaceuticals INC. | $48.06 | 2021-2022 | |
| Global Blood Therapeutics, INC. | $42.82 | 2022 | |
| Amneal Pharmaceuticals LLC | $41.42 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $34.84 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.09 | 2022 | |
| Sk Life Science, INC. | $30.57 | 2023 | |
| Alnylam Pharmaceuticals INC. | $24.99 | 2022 | |
| Eisai INC. | $23.98 | 2022 | |
| Kyowa Kirin, INC. | $23.92 | 2023 | Nourianz |
| Celgene Corporation | $22.14 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.23 | 2019 | |
| Acorda Therapeutics, INC | $17.52 | 2023 | Inbrija, Ampyra |
| Livanova USA, INC. | $17.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Zumo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.